xl 310Alternative Names: Ex4-PAS-PYY; xl-310
Latest Information Update: 09 Aug 2016
At a glance
- Originator XL-protein GmbH
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Metabolic disorders
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 09 Aug 2016 Preclinical trials in Metabolic disorders in Germany (unspecified route)
- 09 Aug 2016 xl 310 is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/